Skip to content

This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.

This is a promotional website intended for licensed healthcare professionals
or prescribed patients in the United Kingdom or Republic of Ireland.
Please select one of the following:

I am a patient

Continue

I am a Healthcare Professional

Outside of the UK

I am a Healthcare Professional
In the UK

UK-VRX-2600029 Date of Last Revision: April 2026

Voraxaze works
in the circulation

Voraxaze® Works in the Circulation to Quickly Clear Methotrexate (MTX)1-3

Voraxaze and Leucovorin Work Differently1,2

  • Voraxaze® (glucarpidase) lowers toxic levels in the extracellular compartment, whereas leucovorin counteracts MTX intracellularly. Only Voraxaze rapidly reduces plasma MTX concentrations by hydrolyzing extracellular MTX
  • Voraxaze rapidly cleaves MTX into 2 inactive metabolites to provide a nonrenal pathway for elimination1,3

VORAXAZE® converts MTX to INACTIVE METABOLITES within 15 minutes1,4

Voraxaze-MOA-molecule_1

Abbreviations: DAMPA, 4-deoxy-4-amino-N10-methylpteroic acid; MTX, methotrexate.

References

  1. Summary of Product Characteristics (SmPC), Voraxaze®
  2. Howard SC, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471-82.
  3. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694-703.

UK-VRX-2600032 Date of Last Revision: February 2026